GNHAY - Vifor Fresenius' rare autoimmune disease drug Tavneos gets UK NICE backing
- Vifor Fresenius Medical Care Renal Pharma said that England's National Institute for Health and Care Excellence (NICE) recommended Tavneos in combination with a rituximab or cyclophosphamide regimen to treat adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), two main forms of ANCA-associated vasculitis (AAV).
- Vifor Fresenius is a joint company of CSL ( OTCPK:CSLLY ) ( OTCPK:CMXHF ) and Fresenius Medical Care ( FMS ). CSL had acquired Vifor Pharma ( OTCPK:GNHAY ) in a ~$11.7B deal.
- U.K. drug pricing watchdog NICE's recommendation will enable eligible patients in England, Wales and Northern Ireland to access the drug.
- Tavneos was approved by the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) in May.
- The company expects to launch Tavneos in the U.K. in the coming weeks.
- AAV is a group of rare autoimmune diseases characterized by damage and inflammation to small vessels and can affect several parts of the body, such as the kidney, stomach, intestine, and lung, among others.
For further details see:
Vifor Fresenius' rare autoimmune disease drug Tavneos gets UK NICE backing